These outcomes told us that in the selection process of Plk1 inhibitors for treating tumors, they might not be very suitable for hematological malignant tumors, such as neutropenia, acute myeloid leukemia and non-Hodgkin lymphoma. This evidence concerns the gene PLK1 and neutropenia.